Corbus Pharmaceuticals Holdings (CRBP) Retained Earnings (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Retained Earnings of $703.0 million for Q4 2025, up 13.52% year-over-year from $619.3 million in Q4 2024, and up 12.11% quarter-over-quarter from $627.0 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Retained Earnings (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Retained Earnings history runs 13 years deep, the most recent figure standing at $703.0 million for Q4 2025.
- In Q4 2025, Retained Earnings rose 13.52% year-over-year to $703.0 million; the TTM figure through Dec 2025 stood at $703.0 million (up 13.52% YoY), while the FY2025 annual figure was $703.0 million, up 13.52% from the prior year.
- Retained Earnings for Q4 2025 stood at $703.0 million, up from $627.0 million in the prior quarter.
- The five-year high for Retained Earnings was $703.0 million in Q4 2025, with the low at -$436.7 million in Q4 2023.
- The 5-year median for Retained Earnings is $427.3 million (2023), against an average of $456.5 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings tumbled 202.7% in 2023, then soared 241.82% in 2024.
- Corbus Pharmaceuticals Holdings' Retained Earnings stood at $418.9 million in 2021, then increased by 1.5% to $425.2 million in 2022, then sank by 202.7% to -$436.7 million in 2023, then jumped by 241.82% to $619.3 million in 2024, then climbed by 13.52% to $703.0 million in 2025.
- Business Quant data shows CRBP's Retained Earnings at $703.0 million in Q4 2025, $627.0 million in Q3 2025, and $622.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | 702.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 702.98 Mn |
| Sep 30, 2025 | 627.02 Mn |
| Jun 30, 2025 | 622.56 Mn |
| Mar 31, 2025 | 621.00 Mn |
| Dec 31, 2024 | 619.29 Mn |
| Sep 30, 2024 | 617.65 Mn |
| Jun 30, 2024 | 579.51 Mn |
| Mar 31, 2024 | 540.88 Mn |
| Dec 31, 2023 | -436.68 Mn |
| Sep 30, 2023 | 428.98 Mn |
| Jun 30, 2023 | 428.15 Mn |
| Mar 31, 2023 | 426.35 Mn |
| Dec 31, 2022 | 425.20 Mn |
| Sep 30, 2022 | 423.34 Mn |
| Jun 30, 2022 | 422.00 Mn |
| Mar 31, 2022 | 420.48 Mn |
| Dec 31, 2021 | 418.90 Mn |
| Sep 30, 2021 | 417.10 Mn |
| Jun 30, 2021 | 414.25 Mn |
| Mar 31, 2021 | 411.69 Mn |